Dyne Therapeutics, Inc. $DYN Shares Acquired by Algert Global LLC

Key Points

• Algert Global LLC significantly increased its stake in Dyne Therapeutics by 488.2%, holding 476,007 shares worth approximately $4.98 million after acquiring an additional 395,084 shares in the 1st quarter.
• CEO John Cox bought 100,000 shares at $9.11 each, raising his total ownership to 242,179 shares, marking a 70.33% increase in his stake.
• Analysts have set a consensus price target of $33.80 for Dyne Therapeutics, with a majority rating the stock as a "Moderate Buy." Several firms have recently adjusted their price targets downward.

Algert Global LLC grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 488.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 476,007 shares of the company's stock after purchasing an additional 395,084 shares during the quarter. Algert Global LLC owned approximately 0.42% of Dyne Therapeutics worth $4,979,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Summit Investment Advisors Inc. increased its holdings in shares of Dyne Therapeutics by 9.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company's stock valued at $203,000 after purchasing an additional 721 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Dyne Therapeutics by 5.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,690 shares of the company's stock valued at $237,000 after acquiring an additional 1,115 shares during the period. Arizona State Retirement System grew its stake in Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock valued at $183,000 after acquiring an additional 1,481 shares during the period. E Fund Management Co. Ltd. grew its stake in Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after acquiring an additional 1,923 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $50,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Up 2.9%

Dyne Therapeutics stock traded up $0.36 during mid-day trading on Friday, hitting $12.58. The company had a trading volume of 2,298,424 shares, compared to its average volume of 3,077,638. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of -3.26 and a beta of 1.08. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $46.81. The business has a fifty day moving average of $10.23 and a 200 day moving average of $11.20. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.02. On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO John Cox acquired 100,000 shares of the company's stock in a transaction that occurred on Monday, July 14th. The stock was purchased at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the transaction, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This trade represents a 70.33% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 14.14% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the company. Robert W. Baird reduced their target price on Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a report on Wednesday, June 18th. Oppenheimer lowered their target price on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 6th. Jones Trading assumed coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They set a "buy" rating and a $30.00 target price on the stock. Guggenheim reaffirmed a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Finally, Stifel Nicolaus lowered their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $33.80.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.